| Revue: | Revista de investigación clínica |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000453223 |
| ISSN: | 0034-8376 |
| Autores: | Kammar García, Ashuin1 Vidal Mayo, José de J1 Vera Zertuche, Juan M2 Lazcano Hernández, Martín3 Vera López, Obdulia3 Segura Badilla, Orietta4 Aguilar Alonso, Patricia3 Navarro Cruz, Addi R3 |
| Instituciones: | 1Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Urgencias, Ciudad de México. México 2Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Departamento de Endocrinología, Ciudad de México. México 3Benemérita Universidad Autónoma de Puebla, Facultad de Ciencias Químicas, Puebla. México 4Universidad del Bío-Bío, Facultad de Ciencias de la Salud y de los Alimentos, Concepción. Chile |
| Año: | 2020 |
| Periodo: | May-Jun |
| Volumen: | 72 |
| Número: | 3 |
| Paginación: | 151-158 |
| País: | México |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Aplicado, descriptivo |
| Resumen en inglés | Background: The coronavirus disease 2019 outbreak is a significant challenge for health-care systems around the world. Objective: The objective of the study was to assess the impact of comorbidities on the case fatality rate (CFR) and the development of adverse events in patients positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the Mexican population. Materials and methods: We analyzed the data from 13,842 laboratory-confirmed SARS-CoV-2 patients in Mexico between January 1, 2020, and April 25, 2020. We investigated the risk of death and the development of adverse events (hospitalization, pneumonia, orotracheal intubation, and intensive care unit [ICU] admission), comparing the number of comorbidities of each patient. Results: The patient mean age was 46.6 ± 15.6 years, 42.3% (n = 5853) of the cases were women, 38.8% of patients were hospitalized, 4.4% were intubated, 29.6% developed pneumonia, and 4.4% had critical illness. The CFR was 9.4%. The risk of hospitalization (odds ratio [OR] = 3.1, 95% confidence interval [CI]: 2.7-3.7), pneumonia (OR = 3.02, 95% CI: 2.6-3.5), ICU admission (OR = 2, 95% CI: 1.5-2.7), and CFR (hazard ratio = 3.5, 95% CI: 2.9-4.2) was higher in patients with three or more comorbidities than in patients with 1, 2, or with no comorbidities. Conclusions: The number of comorbidities may be a determining factor in the clinical course and its outcomes in SARS-CoV-2-positive patients |
| Disciplinas: | Medicina |
| Palabras clave: | Salud pública, COVID-19, SARS-CoV-2, Comorbilidad, Mortalidad, México |
| Keyword: | Public health, COVID-19, SARS-CoV-2, Comorbidity, Mortality, Mexico |
| Texte intégral: | Texto completo (Ver HTML) Texto completo (Ver PDF) |
